Related Experiment Video
Updated: Jun 13, 2026
09:16
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Adenosine A2A Receptor Contributes to Bidirectional Remodeling of Microglial Inflammatory Responses During
Zhenping Hou1, Xinjie Zhang1, Genmeng Yang1
1National Health Commission (NHC) Key Laboratory of Drug Addiction Medicine, School of Forensic Medicine, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong District, Kunming 650500, China.
International Journal of Molecular Sciences
|June 12, 2026
Summary
Methamphetamine (MA) triggers neuroinflammation by altering adenosine A2A receptor (A2AR) expression and signaling in microglia. Blocking A2AR reduces MA-induced inflammation, suggesting it as a therapeutic target for MA abuse.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Methamphetamine (MA) abuse is linked to neurotoxicity and neuroinflammation.
- Microglia play a critical role in mediating neuroinflammation.
- The adenosine A2A receptor (A2AR) is implicated in various neurological processes.
Purpose of the Study:
- To investigate the role of A2AR in MA-induced microglia-mediated neuroinflammation.
- To explore the signaling mechanisms underlying MA-induced neuroinflammation.
- To evaluate A2AR as a potential therapeutic target for MA abuse.
Main Methods:
- Western blotting and immunofluorescence on human striatal tissue, mouse models, and HMC3 cells.
- Analysis of A2AR expression and downstream signaling pathways (PKA, PKC).
- Assessment of pro-inflammatory (iNOS, IL-1β, IL-18) and anti-inflammatory (Arg-1, IL-10) mediators.
- Pharmacological intervention using the A2AR antagonist SCH58261.
Main Results:
- MA exposure upregulated A2AR expression and altered PKA/PKC signaling in microglia.
- MA induced a mixed inflammatory response with simultaneous changes in pro- and anti-inflammatory mediators.
- Inhibition of A2AR with SCH58261 attenuated MA-induced signaling alterations and inflammatory mediator shifts.
- A2AR antagonism mitigated the overall neuroinflammatory response.
Conclusions:
- A2AR is involved in modulating MA-induced microglial inflammatory responses.
- A2AR contributes to the mixed inflammatory state observed in MA neurotoxicity, potentially via PKA/PKC signaling.
- A2AR represents a potential therapeutic target for intervention in MA abuse and related neuroinflammation.
Related Concept Videos
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...